# Clinical efficacy analysis of haploidentical high-dose in vitro non-T-cell-depleted peripheral blood hematopoietic stem cell transplantation for the treatment of adult patients with Ph+ acute lymphoblastic leukemia

## TL;DR

This study evaluates the effectiveness of a specific stem cell transplant method in treating adult patients with a type of leukemia called Ph+ ALL.

## Contribution

The study provides clinical evidence on the efficacy of haploidentical high-dose non-T-cell-depleted stem cell transplantation for Ph+ ALL.

## Key findings

- 25 patients transplanted successfully with hematopoietic recovery achieved in all cases.
- The 2-year overall survival rate was 81.3%, and disease-free survival was 77.1%.
- Low relapse rates and manageable acute GVHD were observed.

## Abstract

分析单倍体相合高剂量非体外去T细胞外周血造血干细胞移植（haplo-HDPSCT）治疗成人Ph+急性淋巴细胞白血病（Ph+ ALL）的疗效。

回顾性分析2011年7月至2022年6月在新疆医科大学第一附属医院血液科接受haplo-HDPSCT模式25例成人Ph+ ALL患者的临床疗效。

25例患者中，男12例，女13例，中位年龄27（16～61）岁。23例移植前处于第1次完全缓解（CR1）状态，2例处于第2次或以上完全缓解（≥CR2）状态，微小残留病（MRD）阳性、阴性分别为8、17例。清髓性预处理21例，减低剂量预处理4例。25例患者移植后均获得造血重建，16例发生急性移植物抗宿主病（GVHD），Ⅱ～Ⅳ、Ⅲ/Ⅳ度急性GVHD累积发生率分别为（40.4±11.3）％、（4.8±4.6）％；移植后1、2年累积复发率分别为（4.0±3.9）％、（14.5±7.9）％。移植后2年总生存、无病生存率分为（81.3±8.5）％、（77.1±9.1）％。

haplo-HDPSCT治疗Ph+ ALL具有较好的疗效。